DRG 375 Overview

DRG 375 covers hospital admissions for patients with malignant gastrointestinal conditions where a Complication or Comorbidity is present, reflecting cases more complex than those without such additional diagnoses. This category typically includes malignancies of the stomach, small intestine, colon, rectum, liver, pancreas, and biliary tract when accompanied by an identified Complication or Comorbidity that affects resource use. It matters for Medicare payment because the presence of a Complication or Comorbidity increases expected resource consumption and therefore adjusts the inpatient reimbursement relative to less complex malignant digestive cases. Accurate coding of the principal diagnosis and any Complications or Comorbidities directly affects the assigned Diagnosis-Related Group and consequent Medicare Severity Diagnosis-Related Group-based payment.

• Perioperative optimization and enhanced recovery trials: Studies in this area evaluate prehabilitation, nutritional interventions, and multimodal pain control protocols for patients undergoing surgery for digestive tract malignancies (e.g., stomach, small bowel, colon, rectum, hepatobiliary neoplasms) who present with complicating conditions such as malnutrition, anemia, or infection. These trials typically enroll hospitalized patients scheduled for elective or urgent resection and measure metrics like complication rates, length of stay, readmission, and short-term functional recovery. Results are directly relevant to inpatient providers who must manage surgical risk and to payers because improved perioperative pathways can reduce costly complications and resource use associated with this DRG.
• Comparative effectiveness studies of systemic and locoregional therapies in patients with advanced or locally complicated digestive malignancies: These trials compare outcomes (tumor response, symptom control, progression-free survival, and hospitalization burden) between different systemic regimens, combinations with locoregional approaches (such as embolization or localized ablation), or timing strategies for patients with metastatic or recurrent disease who often require inpatient care for complications. Patient populations include those with CC (complications/comorbidities) like biliary obstruction, bleeding, or treatment-related toxicity; the clinical question centers on which approaches reduce hospital admissions and severe adverse events while delivering meaningful disease control. Payers and hospital administrators value this research because choosing more effective or lower-toxicity strategies can decrease inpatient utilization, ICU transfers, and downstream costs tied to this DRG.
• Post-discharge outcomes and care coordination research focusing on complication prevention and palliative transitions: These prospective observational studies and intervention trials test discharge planning models, home-based symptom management, and early palliative care integration for patients hospitalized with digestive malignancies who have complications or comorbidities that increase readmission risk. Enrolled patients are those discharged after treatment for obstruction, infection, or treatment complications, and studies measure 30- and 90-day readmissions, emergency visits, symptom burden, and patient-centered outcomes. Findings inform inpatient clinicians and payers about which transition-of-care interventions reduce readmissions, align care with patient goals, and optimize resource use for a population that frequently returns to the hospital.